PNPLA3 and steatosis: The targeting of the PNPLA3 I148M variant in a mouse model using tri-antennary N-acetyl galactosamine (GalNAC3) conjugated with an antisense RNA oligonucleotide (ASO) decreased hepatic inflammation, steatosis and fibrosis [54].